文献リスト

1）Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012; 47: 586–95

2）Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastro-enterology. 2011; 140: 124-31

3）Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an inter-national collaborative study. Hepatology. 2011; 54: 1208-16

4）Calori G, Lattuada G, Ragogna F, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology. 2011; 54: 145-52

5）Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010; 51: 1972-8

6）Valenti L, Al-Serri A, Daly AK, et al. Homo-zygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010; 51: 1209-17

7）Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011; 53: 1883-94

8）Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric non-alcoholic fatty liver disease. Hepatology. 2010; 52: 1274-80

9）Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010; 362: 1082-9

10）Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012; 55: 781-9

11）Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010; 52: 1836-46

12）Lefterova MI, Lazar MA. New developments in adipogenesis. Trends Endocrinol Metab. 2009; 20(3): 107-14

13）Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011; 121(6): 2111-7

14）Holland WL, Bikman BT, Wang LP, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide bio-synthesis in mice. J Clin Invest. 2011; 121(5): 1858-70

15）Zhang X, Xu A, Chung SK, et al. Selective inactivation of c-Jun NH2-terminal kinase in adipose tissue protects against diet-induced obesity and improves insulin sensitivity in both liver and skeletal muscle in mice. Diabetes. 2011; 60(2): 486-95

16）Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and meta-bolic signals. Nat Rev Mol Cell Biol. 2011; 12(3): 141-51

17）Misu H, Takamura T, Takayama H, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010; 12(5): 483-95

18）Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009; 49(6): 1877-87

19）Fukada H, Yamashina S, Izumi K, et al. Suppression of autophagy sensitizes Kupffer cells to endotoxin. Hepatol Res. 2012 Apr 10. in press

20）Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steato-hepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011; 53(6): 1874-82

21）Juluri R, Vuppalanchi R, Olson J, et al. Generalizability of the nonalcoholic steato-hepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2011; 45: 55-8

22）Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009; 50: 1072-8

23）Musso G, Gambino R, Durazzo M, et al. Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Pro-gnostic value of kiver fat equation goes beyond hepatic gat estimation. Hepatology. 2010; 51(2): 715-7

24）Park H, lshigami A, Shima T, et al. Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease．J Gastroenterol. 2010; 45(4): 426-34

25）Bell LN, Theodorakis JL, Vuppalanchi R, et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology. 2010; 51: 111-20

26）Adams LA, Feldstein AE. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis. 2011; 12(1): 10-6

27）Kayadibi H, Gultepe M, Yasar B, et al. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci. 2009; 54: 1764-71

28）Sumida Y, Yoneda M, Hyogo H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011; 46(2): 257-68

29）Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7: 1104-12

30）Sumida Y, Yoneda M, Hyogo H, et al. Validatioin of the FIB 4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastro-enterol. 2012; 12: 2

31）Abenavoli L, Beaugrand M. Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol. 2012; 11(2): 172-8

32）Friedrich-Rust M, Romen D, Vermehren J, et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assess-ment of liver fibrosis and steatosis in NAFLD. Eur J Radiol. 2012; 81(3): e325-31

33）Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51: 121-9

34）Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology. 2010; 52(1): 370-81

35）Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis. N Engl J Med. 2010; 362: 1675-85

36）Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305: 1659-68

37）Torres DM, Jones FJ, Shaw JC, et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology. 2011; 54(5): 1631-9

38）Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for non-alcoholic　steatohepatitis: a　double-blind，randmized，placebo-controlled trial．Hepatology. 2010; 52: 472-9

39）Pathil A, Mueller J, Warth A, et al. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012; 55(5): 1369-78

40）Zein CO, Yerian LM, Gogate P, et al. Pent-oxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011; 54: 1610-9

41）Zein CO, Lopez R, Kirwan JP, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism. Hepatology 2012; 56(4): 1291-9

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp